Benjamin Segerson, DO
Internal Medicine · Clarence, NYNPI 1780047258
Payments from drug & device makers
Across 271 payments — averaging $19.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$784
- Lilly USA, LLC$722
- Novo Nordisk$452
- Boehringer Ingelheim$429
- Pfizer$381
- GSK$361
- plus $2K from 27 others
What the payments were for
- Food & beverage$5,22599%
- Education$321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 37 | $784 |
| Lilly USA, LLC | 42 | $722 |
| Novo Nordisk | 24 | $452 |
| Boehringer Ingelheim | 18 | $429 |
| Pfizer | 21 | $381 |
| GSK | 19 | $361 |
| AbbVie(2 entities) | 12 | $242 |
| Amgen | 12 | $216 |
| Bayer | 14 | $197 |
| Phathom Pharmaceuticals, Inc. | 7 | $182 |
| Sanofi-aventis U.S. LLC | 3 | $154 |
| Kowa Pharmaceuticals America, Inc. | 7 | $131 |
| Exact Sciences | 6 | $113 |
| Biohaven Pharmaceuticals, Inc. | 2 | $104 |
| Abbott | 5 | $98 |
| Amarin Pharma, Inc. | 6 | $95 |
| Johnson & Johnson | 5 | $77 |
| Novartis | 4 | $72 |
| E.r. Squibb & Sons, L.L.C. | 5 | $66 |
| Astellas Pharma US Inc | 3 | $54 |
| Merck | 3 | $43 |
| Esperion Therapeutics, Inc. | 3 | $43 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $33 |
| Edwards Lifesciences | 1 | $31 |
| Mylan Specialty L.p. | 2 | $29 |
| Amneal Pharmaceuticals LLC | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Recordati_rare_diseases_inc. | 1 | $20 |
| EUSA Pharma (US) LLC | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $18 |
| Inspire Medical Systems, Inc. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Corcept Therapeutics | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOLIQUA 100/33$125
- FARXIGA$110
- FASENRA$110
- BREZTRI$110
- AIRSUPRA$110
How this compares
$5,257 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 161 | $167,586 |
| EliquisApixaban | 128 | $155,633 |
| OzempicSemaglutide | 137 | $146,302 |
| MounjaroTirzepatide | 93 | $92,773 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 102 | $90,717 |
| XareltoRivaroxaban | 40 | $57,180 |
| FarxigaDapagliflozin Propanediol | 43 | $44,688 |
| Spiriva RespimatTiotropium Bromide | 44 | $33,237 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 34 | $32,401 |
| RybelsusSemaglutide | 23 | $20,773 |
| TrulicityDulaglutide | 13 | $19,681 |
| TradjentaLinagliptin | 13 | $18,752 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 13 | $17,026 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 74 | $15,021 |
| VascepaIcosapent Ethyl | 12 | $13,106 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta, Synjardy Xr | $429 | $230,542229 claims |
| Novo NordiskOzempic, Rybelsus | $452 | $167,075160 claims |
| PfizerEliquis, Paxlovid | $381 | $159,611158 claims |
| Lilly USA, LLCMounjaro, Trulicity | $722 | $112,455106 claims |
| GSKTrelegy Ellipta | $361 | $90,717102 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $784 | $83,28599 claims |
| Johnson & JohnsonXarelto | $77 | $57,18040 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $154 | $17,02613 claims |
| Astellas Pharma US IncMyrbetriq | $54 | $8,97412 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $23 | $8,285465 claims |
| AbbVieSynthroid | $242 | $5,18783 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Clarence
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.